Clinical Trial Update: A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

This update reports on a Phase 1 clinical trial of JMT601 in relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• JMT601

Snippet

Sponsor: Shanghai JMT-Bio Inc. | Conditions: B-cell Non Hodgkin Lymphoma | Phase 1 | Status: RECRUITING